Menu
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Pharmacovigilance and Risk Management Strategies Conference
Session 14: Hot Topics
Session Chair(s)
Mick Foy
- Deputy Director of Patient Safety Monitoring
- Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
This session will inform attendees about the 3S project. Funded by the Bill and Melinda Gates the WHO are working with low and middle income countries with a high disease burden in specific areas that are subject to new treatments to increase their pharmacovigilance capabilities. MHRA are collaborating in the project to ensure regulatory pharmacovigilance capacity is increased to collect, analyse and act on safety data.
Learning Objective : Upon completion of this session, the participant should be able to:Understand the rationale for 3S- Learn how industry is key to the success of PV in low- and middle-income countries
- Understand the need for robust regulatory frameworks for PV
Speaker(s)
Mick Foy
- Deputy Director of Patient Safety Monitoring
- Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
Triple-s (3S) Smart Safety Surveillance
Raj Long, MEd, MSc
- Deputy Director, Safety and Pharmacovigilance
- Bill and Melinda Gates Foundation, United Kingdom
Contact us
Customer Service
Preconference Short Courses
Short Course 1: Introduction to Pharmacoepidemiology
Short Course 2: Pharmacovigilance and Risk Management Planning
Short Course 3: Reference Safety Information
Short Course 4: Combination Therapies